Investment round documentation for Nextvet BioPharma

Nexvet is using its expertise to develop biological drugs for companion animals that are specific equivalents of blockbuster human biopharmaceuticals. The therapeutic focus is on pain, cancer and inflammatory diseases for dogs, cats and horses. Commercialisation Australia funding will be used to secure specialist advice and reports to support a significant capital raising to finance the expansion of the product portfolio.